rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David S. Tierney

Director

Company insider

Files Form 4 as: Director, Catalyst Pharmaceutical; Director, Zevra Therapeutics; Pres and CEO, BioPharmX; Director, Bioject Medical Technologies; Director, Nexmed; President and CEO, Valera Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
179
Buys
12
Sells
8
Bought
$221K
Sold
$3.0M
Companies
6
Companies where not an officer
4
First trade
1 Feb 2006
Last trade
15 Jul 2026
Last filed
17 Jul 2026

Companies traded

Where they are an officer
BioPharmXDirector, Officer · last 12 Jun 20191 buy · 0 sells
Valera PharmaceuticalsDirector, Officer · last 17 Apr 20072 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Catalyst PharmaceuticalDirector · Biotechnology · last 15 Jul 20263 buys · 8 sells
ZVRA Zevra TherapeuticsDirector · Biotechnology · last 9 Mar 20236 buys · 0 sells
Bioject Medical TechnologiesDirector · last 30 Apr 20140 buys · 0 sells
NexmedDirector · last 6 Oct 20090 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Jul 2026filed 17 Jul 2026Catalyst PharmaceuticalBiotechnologySEC FORM 4 Code D$12.1M383,314 at $31.50filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—1,894 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—5,468 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—33,500 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—30,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—33,500 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—30,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—20,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—15,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—29,524 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—23,248 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—18,115 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—1,414 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—1,894 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—5,468 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—20,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—15,000 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—29,524 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—23,248 at $0.00filing
15 Jul 2026filed 17 Jul 2026Catalyst Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code D—18,115 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care6
Not placed14

Buys in green, sells in red, by the company’s sector.

Related people

Neil F. McFarlanePresident and CEO · Also traded ZVRA in the last 90 days
Rahsaan ThompsonChief Legal & Compliance · Also traded ZVRA in the last 90 days
Corey Michael WattonDirector · Also traded ZVRA in the last 90 days